COMPANY:

GC Genome

"GC Genome Corporation...presented new data from its AI-based liquid biopsy platform for non-invasive colorectal cancer (CRC) detection at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting....The poster presentation highlighted the potential implementation of its liquid biopsy platform using multimodal deep learning technology to detect colorectal cancer in clinical data. The study incorporates 1,506 colonoscopy-verified normal samples, 130 AA patients, and 302 CRC patients (with a breakdown of stages)....The multimodal deep learning algorithm achieved high sensitivity for CRC detection, ranging from 80.2% to 84.0% across all stages. The algorithm also demonstrated promising accuracy in detecting AA lesions, with a sensitivity of 63.0%. The use of colonoscopy-verified normal samples strengthens the study's foundation and paves the way for future clinical translation."

"GC Genome Corporation...announced that it will present the new clinical data of its AI-based liquid biopsy platform on colorectal cancer detection at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 31–June 4. This research was conducted through a collaborative effort with Genece Health Inc., a strategic partner based in San Diego."

"GC Genome Corporation...today announced that the company will present two poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, California, from April 5–10, 2024. During the event, GC Genome will showcase the innovative performance of its liquid biopsy technology for early cancer detection using cfDNA, highlighting its effectiveness across diverse ethnic groups."

"GC Genome Corporation...announced that it has entered into a collaboration and exclusive license agreement with MP Group CO., LTD, Bangkok, Thailand to commercialize 'Genome Health' for genetic health checkups."

"GC Genome Corporation...announced the publication of a new study in Journal of the National Cancer Institute (JNCI), shedding light on the remarkable potential of utilizing circulating tumor DNA (ctDNA) copy number aberration (CNA) for prognosis prediction and molecular profiling in cancer patients in collaboration with the team of Dr. Joohyuk Sohn, MD, professor at Severance Hospital."

"GC Genome Corporation...announced that the company will present data showcasing the deep learning algorithm that detects and classifies multi-cancer using methylation information and genomic data at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, Florida."